Difference between revisions of "Alpha-methylacyl-CoA racemase"
Jump to navigation
Jump to search
(→General: tweak) |
|||
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{ Infobox immunostain | |||
| Name = {{PAGENAME}} | |||
| Image = Atypical_small_acinar_proliferation_-_AMACR-CK34betaE12_-_alt_--_very_high_mag.jpg | |||
| Width = | |||
| Caption = AMACR positivity in [[ASAP]]. CK5/6-AMACR immunostain | |||
| Abbrev = AMACR | |||
| Synonyms = racemase | |||
| Similar = | |||
| Clones = | |||
| Use = | |||
| Subspecial = [[genitourinary pathology]] | |||
| Pattern = cytoplasmic | |||
| Positive = [[prostate carcinoma]] ~90%, [[high grade prostatic intraepithelial neoplasia]], [[urothelial carcinoma]] ~50%, [[papillary renal cell carcinoma]] | |||
| Negative = [[clear cell papillary renal cell carcinoma]] (clear cell tubulopapillary RCC) | |||
| Other = | |||
}} | |||
'''Alpha-methylacyl-CoA racemase''', abbreviated '''AMACR''', is a commonly used [[immunostain]] in [[genitourinary pathology]]. | '''Alpha-methylacyl-CoA racemase''', abbreviated '''AMACR''', is a commonly used [[immunostain]] in [[genitourinary pathology]]. | ||
==General== | |||
AMACR converts [[testosterone]] to hydrotestosterone.<ref name=pmid8626825>{{Cite journal | last1 = Cai | first1 = LQ. | last2 = Zhu | first2 = YS. | last3 = Katz | first3 = MD. | last4 = Herrera | first4 = C. | last5 = Baéz | first5 = J. | last6 = DeFillo-Ricart | first6 = M. | last7 = Shackleton | first7 = CH. | last8 = Imperato-McGinley | first8 = J. | title = 5 alpha-reductase-2 gene mutations in the Dominican Republic. | journal = J Clin Endocrinol Metab | volume = 81 | issue = 5 | pages = 1730-5 | month = May | year = 1996 | doi = 10.1210/jcem.81.5.8626825 | PMID = 8626825 }}</ref> | |||
==Positive== | ==Positive== | ||
| Line 8: | Line 27: | ||
==Positive or negative== | ==Positive or negative== | ||
*[[Nephrogenic adenoma]]. | *[[Nephrogenic adenoma]]. | ||
*[[Urothelial carcinoma]] - not useful for | *[[Urothelial carcinoma]] - not useful for prostate versus bladder; it is positive in ~50% of [[UCC]].<ref name=pmid16315020>{{Cite journal | last1 = Langner | first1 = C. | last2 = Rupar | first2 = G. | last3 = Leibl | first3 = S. | last4 = Hutterer | first4 = G. | last5 = Chromecki | first5 = T. | last6 = Hoefler | first6 = G. | last7 = Rehak | first7 = P. | last8 = Zigeuner | first8 = R. | title = Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. | journal = Virchows Arch | volume = 448 | issue = 3 | pages = 325-30 | month = Mar | year = 2006 | doi = 10.1007/s00428-005-0129-6 | PMID = 16315020 }}</ref> | ||
==Negative== | ==Negative== | ||
*[[Clear cell papillary renal cell carcinoma]]. | *[[Clear cell papillary renal cell carcinoma]]. | ||
==Images== | |||
<gallery> | |||
Image: Prostate carcinoma with inflammation - ck5-6-amacr -- low mag.jpg | [[Prostatic carcinoma]] - CK5/6-AMACR - low mag. (WC) | |||
Image: Prostate carcinoma with inflammation - ck5-6-amacr -- intermed mag.jpg | Prostatic carcinoma - CK5/6-AMACR - intermed. mag. (WC) | |||
Image: Prostate carcinoma with inflammation - alt - ck5-6-amacr -- intermed mag.jpg | Prostatic carcinoma - CK5/6-AMACR - intermed. (WC) | |||
Image: Prostate carcinoma with inflammation - ck5-6-amacr -- high mag.jpg | Prostatic carcinoma - CK5/6-AMACR - high mag. (WC) | |||
</gallery> | |||
==See also== | ==See also== | ||
Latest revision as of 12:32, 14 April 2018
| Alpha-methylacyl-CoA racemase | |
|---|---|
| Immunostain in short | |
 AMACR positivity in ASAP. CK5/6-AMACR immunostain | |
| Abbreviation | AMACR |
| Synonyms | racemase |
| Subspeciality | genitourinary pathology |
| Normal staining pattern | cytoplasmic |
| Positive | prostate carcinoma ~90%, high grade prostatic intraepithelial neoplasia, urothelial carcinoma ~50%, papillary renal cell carcinoma |
| Negative | clear cell papillary renal cell carcinoma (clear cell tubulopapillary RCC) |
Alpha-methylacyl-CoA racemase, abbreviated AMACR, is a commonly used immunostain in genitourinary pathology.
General
AMACR converts testosterone to hydrotestosterone.[1]
Positive
- Prostate adenocarcinoma.[2]
- Papillary renal cell carcinoma.[3]
- High-grade prostatic intraepithelial neoplasia.
Positive or negative
- Nephrogenic adenoma.
- Urothelial carcinoma - not useful for prostate versus bladder; it is positive in ~50% of UCC.[4]
Negative
Images
Prostatic carcinoma - CK5/6-AMACR - low mag. (WC)
Prostatic carcinoma - CK5/6-AMACR - intermed. mag. (WC)
Prostatic carcinoma - CK5/6-AMACR - intermed. (WC)
Prostatic carcinoma - CK5/6-AMACR - high mag. (WC)
See also
References
- ↑ Cai, LQ.; Zhu, YS.; Katz, MD.; Herrera, C.; Baéz, J.; DeFillo-Ricart, M.; Shackleton, CH.; Imperato-McGinley, J. (May 1996). "5 alpha-reductase-2 gene mutations in the Dominican Republic.". J Clin Endocrinol Metab 81 (5): 1730-5. doi:10.1210/jcem.81.5.8626825. PMID 8626825.
- ↑ Lloyd, MD.; Yevglevskis, M.; Lee, GL.; Wood, PJ.; Threadgill, MD.; Woodman, TJ. (Apr 2013). "α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S.". Prog Lipid Res 52 (2): 220-30. doi:10.1016/j.plipres.2013.01.001. PMID 23376124.
- ↑ Molinié, V.; Balaton, A.; Rotman, S.; Mansouri, D.; De Pinieux, I.; Homsi, T.; Guillou, L. (Jun 2006). "Alpha-methyl CoA racemase expression in renal cell carcinomas.". Hum Pathol 37 (6): 698-703. doi:10.1016/j.humpath.2006.01.012. PMID 16733210.
- ↑ Langner, C.; Rupar, G.; Leibl, S.; Hutterer, G.; Chromecki, T.; Hoefler, G.; Rehak, P.; Zigeuner, R. (Mar 2006). "Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.". Virchows Arch 448 (3): 325-30. doi:10.1007/s00428-005-0129-6. PMID 16315020.